Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A human bioavailability study of CMIO-OLNZ for the treatment of poly ADP ribose polymerase (PARP) inhibitor induced nausea and vomiting

Next Previous
Trial Profile

A human bioavailability study of CMIO-OLNZ for the treatment of poly ADP ribose polymerase (PARP) inhibitor induced nausea and vomiting

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary) ; Olanzapine
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ChemioCare; Starton Therapeutics

Most Recent Events

  • 26 Dec 2019 New trial record
  • 18 Dec 2019 According to an ChemioCare Media Release, the company received an exemption from the U.S. Food and Drug Administration (FDA) from the requirements for an Investigational New Drug application ('IND') to execute the BA study in healthy volunteers.
  • 18 Dec 2019 According to an ChemioCare Media Release, the company announced the completion of a human bioavailability study of CMIO-OLNZ. All endpoints and objectives of the study were met.The results from this study inform the patch size to be manufactured for the planned Phase 3 clinical study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top